



Company Announcement no. 27/2008

To: OMX Nordic Exchange Copenhagen

Hørsholm, Denmark, August 14, 2008

### **LifeCycle Pharma's Updated Financial Calendar 2008**

LifeCycle Pharma A/S (OMX:LCP) issues today an updated financial calendar for 2008:

**August 21, 2008:** Interim Report for 2<sup>nd</sup> Quarter – for the period ending June 30, 2008.

**November 27, 2008:** Interim Report for 3<sup>rd</sup> Quarter – for the period ending September 30, 2008.

**Contact:**

LifeCycle Pharma A/S  
Hans Christian Teisen  
Executive Vice President and CFO  
+45 7033 3300  
[HCT@lcpharma.com](mailto:HCT@lcpharma.com)

**About LifeCycle Pharma A/S ("LCP")**

*LCP is an emerging specialty pharmaceutical company that, through innovative technologies, is able to rapidly develop a portfolio of differentiated products to meet the unique needs of key therapeutic markets and patient populations. This includes products for immunosuppression, specifically organ transplantation, and to combat certain cardiovascular diseases. By using its unique and patented delivery technology, MeltDose<sup>®</sup>, LCP is able to develop drugs with enhanced absorption and thereby increased bioavailability. LCP has a cholesterol lowering product, Fenoglide<sup>™</sup>, currently on the US market and a diversified near- and medium-term pipeline, including four product candidates in clinical trials and two in preclinical stages of development. LCP is listed on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX: LCP). For further information, please visit [www.lcpharma.com](http://www.lcpharma.com).*

LIFECYCLE PHARMA A/S  
KOGLE ALLÉ 4  
DK-2970 HØRSHOLM  
WWW.LIFECYCLEPHARMA.COM

TEL. +45 7033 3300  
FAX +45 3613 0319  
CVR. 26 52 77 67  
INFO@LCPHARMA.COM

page 1 of 1